AstraZeneca's stock experienced a significant decline after the company announced that its late-stage trial for Wainua, aimed at treating transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), failed to meet its primary endpoint. The trial sought to demonstrate a reduction in deaths and recurrent heart-related emergencies over a 140-week period compared to a placebo.
Despite this setback, a Jefferies analyst indicated that the outcome does not threaten AstraZeneca's ambitious $80 billion sales target by 2030, although the company had expressed strong confidence in the trial's success.
The condition affects approximately half a million individuals, and the stock's drop marks its worst performance since March 2020, reflecting investor concerns over the implications of the trial results on the company's future prospects